Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1725-1738

  Aquilante, Christina L ^a   Kiser, Jennifer J ^a   Anderson, Peter L ^a   Christians, Uwe ^b   Kosmiski, Lisa A ^b   Daily, Elizabeth B ^a   Hoffman, Keith L ^b   Hopley, Charles W ^a   Predhomme, Julie A ^a   Schniedewind, Bjorn ^b   Sidhom, Maha S ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Darunavir; drug drug interaction; OATP1B1; pravastatin; ritonavir; SLCO1B1

Indexed keywords

CYTOCHROME P450 3A4; DARUNAVIR PLUS RITONAVIR; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MORNING DOSAGE; NORMAL HUMAN; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHOLESTEROL; DRUG INTERACTIONS; FEMALE; HAPLOTYPES; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; PRAVASTATIN; RITONAVIR; SULFONAMIDES; TRIGLYCERIDES;

EID: 84868020449     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011427907     Document Type: Article

References (77)

1. Pau AK, Boyd SD.. Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy. Clin Pharmacol Ther. 2010 ; 88: 712-719
2. Hsu A, Granneman GR, Bertz RJ.. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998 ; 35: 275-291 (Pubitemid 28491214)
3. King JR, Wynn H, Brundage R, Acosta EP.. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004 ; 43: 291-310 (Pubitemid 38534753)
4. Fichtenbaum CJ, Gerber JG.. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002 ; 41: 1195-1211 (Pubitemid 35398692)
5. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 ; 16: 569-577 (Pubitemid 34218852)
6. Burger D, Stroes E, Reiss P.. Drug interactions between statins and antiretroviral agents. Curr Opin HIV AIDS. 2008 ; 3: 247-251 (Pubitemid 351521006)
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Published January10, 2011. Accessed March 25, 2011.
8. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 ; 37: 613-627 (Pubitemid 37100800)
9. Jacobsen W, Kirchner G, Hallensleben K, et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther. 1999 ; 291: 131-139 (Pubitemid 29451582)
10. Jacobsen W, Kirchner G, Hallensleben K, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 ; 27: 173-179 (Pubitemid 29072068)
11. Neuvonen PJ.. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010 ; 11: 323-332
12. Williams D, Feely J.. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002 ; 41: 343-370 (Pubitemid 34713089)
13. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 ; 274: 17159-17163
14. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 ; 274: 37161-37168
15. Konig J, Cui Y, Nies AT, Keppler D.. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000 ; 278: G156 - G164
16. Annaert P, Ye ZW, Stieger B, Augustijns P.. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010 ; 40: 163-176
17. Campbell SD, de Morais SM, Xu JJ.. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact. 2004 ; 150: 179-187 (Pubitemid 39463281)
18. Tirona RG, Leake BF, Wolkoff AW, Kim RB.. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 ; 304: 223-228 (Pubitemid 36008932)
19. Ye ZW, Augustijns P, Annaert P.. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008 ; 36: 1315-1321 (Pubitemid 351929316)
20. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW.. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008 ; 47: 570-578 (Pubitemid 351442013)
21. Pham PA, la Porte CJ, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009 ; 53: 4385-4392
22. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007 ; 12: 1127-1132 (Pubitemid 350114993)
23. Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin [published online ahead of print June 28, 2011]. J Clin Pharmacol. :
24. Kivisto KT, Grisk O, Hofmann U, et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR-rats. Drug Metab Dispos. 2005 ; 33: 1593-1596 (Pubitemid 41539954)
25. Kivisto KT, Niemi M.. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007 ; 24: 239-247 (Pubitemid 46072183)
26. Singhvi SM, Pan HY, Morrison RA, Willard DA.. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990 ; 29: 239-243 (Pubitemid 20131424)
27. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Paper presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy ; Budapest, Hungary ;..
28. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005 ; 78: 388-399 (Pubitemid 41393674)
29. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M.. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008 ; 84: 488-496
30. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 ; 78: 191-201
31. Suwannakul S, Ieiri I, Kimura M, et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet. 2008 ; 53: 899-904
32. Niemi M, Pasanen MK, Neuvonen PJ.. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 ; 63: 157-181
33. Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 ; 17: 647-656 (Pubitemid 47057714)
34. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006 ; 79: 419-426
35. Niemi M, Pasanen MK, Neuvonen PJ.. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 ; 80: 356-366 (Pubitemid 44465886)
36. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 ; 14: 429-440 (Pubitemid 38971233)
37. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 ; 73: 554-565 (Pubitemid 37249126)
38. Tirona RG, Leake BF, Merino G, Kim RB.. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001 ; 276: 35669-35675
39. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008 ; 359: 789-799
40. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006 ; 79: 427-439
41. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T.. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004 ; 75: 415-421 (Pubitemid 38534562)
42. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://www.niaid.nih.gov/labsandresources/resources/ daidsclinrsrch/documents/daidsaegradingtable.pdf. Published December2004. Accessed March 25, 2011.
43. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA.. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008 ; 3: 7-16
44. Friedewald WT, Levy RI, Fredrickson DS.. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502
45. Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol. 2006 ; 61: 706-715 (Pubitemid 43794798)
46. Lee LS, Nafziger AN, Bertino JS. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther. 2005 ; 78: 1-6 (Pubitemid 40956925)
47. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993 ; 44: 349-355 (Pubitemid 23153452)
48. Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000 ; 67: 466-477 (Pubitemid 30327485)
49. Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T.. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenet Genomics. 2005 ; 15: 851-859 (Pubitemid 41666767)
50. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T.. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004 ; 44: 1223-1229 (Pubitemid 39391480)
51. Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004 ; 57: 487-494 (Pubitemid 38519654)
52. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010 ; 9: 215-236
53. Griffin L, Annaert P, Brouwer KL.. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci. 2011 ; 100: 3636-3654
54. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS.. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999 ; 56: 383-389 (Pubitemid 29347615)
55. Gupta A, Zhang Y, Unadkat JD, Mao Q.. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 ; 310: 334-341 (Pubitemid 38812728)
56. Fujimoto H, Higuchi M, Watanabe H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 ; 32: 1588-1593
57. Bierman WF, Scheffer GL, Schoonderwoerd A, et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother. 2010 ; 65: 1672-1680
58. Ye ZW, Camus S, Augustijns P, Annaert P.. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 ; 31: 178-188
59. Konig SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J.. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 ; 65: 2319-2328
60. Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008 ; 51: 605-610
61. Nakagomi-Hagihara R, Nakai D, Tokui T.. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 ; 37: 416-426 (Pubitemid 46572887)
62. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ.. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003 ; 73: 538-544 (Pubitemid 37249124)
63. Watanabe T, Kusuhara H, Debori Y, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 ; 39: 1031-1038
64. Kohlrausch FB, de Cassia Estrela R, Barroso PF, Suarez-Kurtz G.. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010 ; 69: 95-98
65. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010 ; 20: 217-230
66. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010 ; 20: 112-120
67. Sekar VJ, Ryan R, Schaible D, Mazikewich A, Mrus J.. Pharmacokinetic profile of darunavir co-administered with low-dose ritonavir in treatment-experienced women and men with HIV infection: 4-week analysis in a substudy of the GRACE (Gender, Race, And Clinical Experience) study. Paper presented at: Ninth International Workshop on Clinical Pharmacology of HIV Therapy ; New Orleans, LA ;..
68. Prezista (darunavir) prescribing information. http://www.prezista.com/ sites/default/files/pdf/us-package-insert.pdf. Published December2010. Accessed June 28, 2011.
69. Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men [published online ahead of print January 13, 2011]. J Clin Pharmacol. :
70. Triscari J, O'Donnell D, Zinny M, Pan HY.. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol. 1995 ; 35: 142-144
71. Pravachol (pravastatin) prescribing information. http://packageinserts. bms.com/pi/pi-pravachol.pdf. Published July2010. Accessed on March 25, 2011.
72. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH.. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991 ; 19: 740-748
73. Rittweger M, Arasteh K.. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007 ; 46: 739-756 (Pubitemid 47347446)
74. Prezista (darunavir) prescribing information. http://www.accessdata.fda. gov/drugsatfda-docs/label/2008/021976s003s004lbl.pdf. Published February2008. Accessed on June 28, 2011.
75. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006 ; 20: 725-729 (Pubitemid 43884300)
76. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y.. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009 ; 328: 652-662
77. Watanabe T, Kusuhara H, Sugiyama Y.. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn. 2010 ; 37: 575-590